Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-α

The binding of tumor necrosis factor alpha (TNF-α) to the type-1 TNF receptor (TNFRc1) plays an important role in inflammation. Despite the clinical success of biologics (antibodies, soluble receptors) for treating TNF-based autoimmune conditions, no potent small molecule antagonists have been developed. Our screening of chemical libraries revealed that N-alkyl 5-arylidene-2-thioxo-1,3-thiazolidin-4-ones were antagonists of this protein–protein interaction. After chemical optimization, we discovered IW927, which potently disrupted the binding of TNF-α to TNFRc1 (IC50 = 50 nM) and also blocked TNF-stimulated phosphorylation of Iκ-B in Ramos cells (IC50 = 600 nM). This compound did not bind detectably to the related cytokine receptors TNFRc2 or CD40, and did not display any cytotoxicity at concentrations as high as 100 μM. Detailed evaluation of this and related molecules revealed that compounds in this class are “photochemically enhanced” inhibitors, in that they bind reversibly to the TNFRc1 with weak affinity (ca. 40–100 μM) and then covalently modify the receptor via a photochemical reaction. We obtained a crystal structure of IV703 (a close analog of IW927) bound to the TNFRc1. This structure clearly revealed that one of the aromatic rings of the inhibitor was covalently linked to the receptor through the main-chain nitrogen of Ala-62, a residue that has already been implicated in the binding of TNF-α to the TNFRc1. When combined with the fact that our inhibitors are reversible binders in light-excluded conditions, the results of the crystallography provide the basis for the rational design of nonphotoreactive inhibitors of the TNF-α–TNFRc1 interaction.

[1]  M. Chen,et al.  Site-directed mutational analysis of human tumor necrosis factor-alpha receptor binding site and structure-functional relationship. , 1992, The Journal of biological chemistry.

[2]  A G Porter,et al.  Aspartic acid 50 and tyrosine 108 are essential for receptor binding and cytotoxic activity of tumour necrosis factor beta (lymphotoxin). , 1991, Protein engineering.

[3]  L. Tartaglia,et al.  Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. , 1993, The Journal of biological chemistry.

[4]  N. Ismail,et al.  Voltammetric studies on some substituted 5-arylidene-2-thiohydantoin in non aqueous medium , 1992 .

[5]  S. Sprang,et al.  Two crystal forms of the extracellular domain of type I tumor necrosis factor receptor. , 1994, Journal of Molecular Biology.

[6]  R. Murali,et al.  Structure–based design and characterization of exocyclic peptidomimetics that inhibit TNFα binding to its receptor , 1997, Nature Biotechnology.

[7]  T. Ishida,et al.  Structural elucidation of epalrestat(ONO-2235), a potent aldose reductase inhibitor, and isomerization of its double bonds , 1989 .

[8]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[9]  R. Locksley,et al.  The TNF and TNF Receptor Superfamilies Integrating Mammalian Biology , 2001, Cell.

[10]  K. Bush,et al.  The synthesis and SAR of rhodanines as novel class C β-lactamase inhibitors , 2000 .

[11]  R M Siegel,et al.  A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. , 2000, Science.

[12]  R. Stroud,et al.  Site-directed ligand discovery. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[13]  D. Wallach,et al.  Cytoplasmic truncation of the p55 tumour necrosis factor (TNF) receptor abolishes signalling, but not induced shedding of the receptor. , 1992, The EMBO journal.

[14]  George Kollias,et al.  On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease , 1999, Immunological reviews.

[15]  D. Banner,et al.  Human tumor necrosis factor alpha (TNF alpha) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors. , 1993, The Journal of biological chemistry.

[16]  T. Mitchison,et al.  Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL , 2001, Nature Cell Biology.

[17]  K. Shimotohno,et al.  Novel hepatitis C virus protease inhibitors: thiazolidine derivatives. , 1997, Biochemical and biophysical research communications.

[18]  C R Kissinger,et al.  Rapid automated molecular replacement by evolutionary search. , 1999, Acta crystallographica. Section D, Biological crystallography.

[19]  D. Shealy,et al.  Identification of TNF-alpha binding peptides from a D-amino acid hexapeptide library that specifically inhibit TNF-alpha binding to recombinant p55 receptor. , 1999, Cytokine.

[20]  Massimo Mabilia,et al.  Inhibition of tumor necrosis factor-α (TNF-α)/ TNF-α receptor binding by structural analogues of suramin , 1999 .

[21]  I. Weber,et al.  Model complexes of tumor necrosis factor-alpha with receptors R1 and R2. , 1995, Protein engineering.

[22]  W. Fiers,et al.  Induced Expression of Trimerized Intracellular Domains of the Human Tumor Necrosis Factor (TNF) p55 Receptor Elicits TNF Effects , 1997, The Journal of cell biology.

[23]  C. Decicco,et al.  Therapeutic potential and strategies for inhibiting tumor necrosis factor-alpha. , 1999, Journal of medicinal chemistry.

[24]  S R Sprang,et al.  Crystallographic Evidence for Dimerization of Unliganded Tumor Necrosis Factor Receptor (*) , 1995, The Journal of Biological Chemistry.

[25]  D. Banner,et al.  Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: Implications for TNF receptor activation , 1993, Cell.